Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Vitamin E in Preventing Contrast-Induced Acute Kidney Injury Following Coronary Angiography

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. All patients whon have either stable coronary artery disease (CAD) or recent acute coronary disease (ACS) and are scheduled for coronary angiography.~2. Patients who have eGFR ≤60 ml/min/1.73 m2~Exclusion Criteria:~1. Allergy to contrast media~2. Cardiogenic shock~3. Pulmonary edema~4. Overt cardiac failure or left ventricular ejection fraction ≤ 30%~5. Acute kidney injury~6. The history of receiving contrast media for any medical diagnostic or therapeutic procedures during previous 5 days~7. The history of dialysis~8. Being pregnant~9. Having recent acute myocardial infarction~10. Taking antioxidants and nephrotoxic drugs including NSAID and ACE-I on previous 2 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Vit-E (Type: ACTIVE_COMPARATOR): 600 IU on 12 hours before angiography and 400 IU on 2 hours before angiography

Based on this trial design, predict the completion outcome and termination type (if applicable).